Abstract: Objective To investigate the clinical effect of trimetazidine combined with bisoprolol on the treatment of ischemic cardiomyopathy and its effect on N terminal pro B type natriuretic peptide(NT-proBNP) and cardiac function. Methods Total 86 patients with ischemic cardiomyopathy admitted to Haikou Third People's Hospital from January 2016 to October 2018 were randomly divided into two groups:control group treated with bisoprolol and study group treated with trimetazidine and bisoprolol, 43 cases in each group. After 3 months of treatment, the changes of heart function indexes and NT proBNP level were observed. Results The total clinical effective rate of the study group was 90.70%, which was significantly higher than that of the control group(74.42%, P<0.05). After treatment, the levels of LVEDd and LVESd in the two groups were significantly decreased, and the levels of LVEF were significantly increased. The improvement of the indexes in the study group was significantly better than those in the control group(all P<0.05). After treatment, the levels of NT-proBNP in both groups were significantly decreased, and the degree of reduction in the study group was significantly better than that in the control group(P<0.05). Conclusion Trimetazidine combined with bisoprolol can significantly improve the cardiac function of patients with ischemic cardiomyopathy, reduce NT-proBNP level, and improve the total efficiency of clinical treatment. It is worth popularizing.